Search Results

Endologix LLC, a leader in the treatment of vascular disease, today announced it has completed the acquisition of PQ Bypass, Inc., a privately held medical technology company pioneering a first-of-its-kind technology that addresses an unmet need for new treatments for severe peripheral arterial disease (PAD).

PQ Bypass, Inc., a medical device company pioneering innovative advancements in the treatment of complex Peripheral Artery Disease (PAD), names Heather Simonsen as its President. With this appointment, PQ Bypass now outperforms 90% of Health Technology companies with regards to women representation at the ex

As traditional fundraising methods falter for smaller firms, the rise of royalty deals is reshaping how companies access capital, offering an alternative that bypasses equity dilution and debt.

PQ Bypass Inc, a medical device pioneer bringing new advancements to the treatment of advanced peripheral artery disease (PAD), announced today that they received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Detour System.

PQ Bypass, an innovative medical device company pioneering advancements in the treatment of complex peripheral artery disease (PAD), announces enrollment of the final subject in the company’s flagship IDE, the DETOUR2 clinical trial. This important milestone occurs only a month after the Detour System entered the U.S. Food and Drug Administra

Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the initiation of the PTAB1 Post-Market Study.

PQ Bypass, a medical device manufacturer based in California, announced that DETOUR2 will take the stage during the 10th Annual Amputation Prevention Symposium, the leading meeting dedicated to the treatment and prevention of critical limb ischemia.

Silicon Valley-based medical device company PQ Bypass announced today the 100th patient in the DETOUR2 Clinical Trial, which evaluates the safety and effectiveness of the minimally invasive DETOUR procedure for percutaneous femoropopliteal bypass.